LSD1-IN-19

• UNSPSC Description:

  LSD1-IN-19 (compound 29) is a potent, non-covalent and selective LSD1 inhibitor, with Ki of 0.108 μM and KD of 0.068 μM, respectively. LSD1-IN-19 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC50 (72 h) of 0.17 and 0.40 μM, respectively[1].

• Target Antigen:

  Histone Demethylase

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/lsd1-in-19.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC1=CC2=C(N=C(N=C2NC3CCN(CC3)CC4=CC=CC=C4)NCCCN(C)C)C=C1OCC5=CC=CC=C5

• Molecular Weight:

  554.73

• References & Citations:

  [1]Menna M, et al. Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models. Eur J Med Chem. 2022 Jul 5;237:114410.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2983011-81-8